EQS-News: RHÖN-KLINIKUM AG starts financial year 2024 with a good first quarter
|
EQS-News: RHÖN-KLINIKUM Aktiengesellschaft
/ Key word(s): Quarter Results/Quarter Results
Corporate News
RHÖN-KLINIKUM AG, one of the leading healthcare providers in Germany, has made a solid start to financial year 2024. Both consolidated profit and EBITDA as well as revenues rose in the first three months. Revenues increased by 5.9% to €382.8 million (Q1 2023: €361.5 million). At €25.2 million, EBITDA (earnings before interest, taxes, depreciation and amortisation) was 12% higher than the previous year (Q1 2023: €22.5 million). Taking into account depreciation, amortisation, financing costs and taxes, EBITDA resulted in a consolidated profit of €11.1 million (Q1 2023: €6.4 million). From January to March 2024, 234,151 outpatients and inpatients were treated in the Group's hospitals and medical care centers (Q1 2023: 228,189). “RHÖN-KLINIKUM AG considers itself well prepared for the forthcoming hospital reform with positioning of its hospitals. With our RHÖN Campus concept, the growing range of outpatient treatment services and the establishment of new medical services, we are seizing opportunities that we will implement for the benefit of our patients”, says Prof. Dr Tobias Kaltenbach, Chairman of the Board of Management of RHÖN-KLINIKUM AG.
For the coming financial year, RHÖN-KLINIKUM AG expects revenues of €1.6 billion euros within a range of +/- 5% upwards and downwards respectively. For earnings before interest, tax and depreciation and amortisation (EBITDA), a level of between €110 million euros and €120 million is expected. This outlook reflects the further tightening of regulatory intervention by the legislator. RHÖN-KLINIKUM AG points out that the outlook is subject to considerable uncertainties in connection with the numerous global crises resulting in inflation and price increases and subject to any regulatory intervention causing the remuneration structure in 2024.
RHÖN-KLINIKUM AG is one of the leading healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 882,000 patients are treated at our five sites – RHÖN-KLINIKUM Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs over 18,200 persons. The innovative RHÖN Campus approach committed to cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with Asklepios are key elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA. www.rhoen-klinikum-ag.com
RHÖN-KLINIKUM AG |Head of Corporate Finance, Treasury, Investor Relations and Sustainability
08.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | RHÖN-KLINIKUM Aktiengesellschaft |
| Salzburger Leite 1 | |
| 97616 Bad Neustadt a.d.Saale | |
| Germany | |
| Phone: | +49 (0)9771 - 65-0 |
| Fax: | +49 (0)9771 - 97 467 |
| E-mail: | rka@rhoen-klinikum-ag.com |
| Internet: | www.rhoen-klinikum-ag.com |
| ISIN: | DE0007042301 |
| WKN: | 704230 |
| Listed: | Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1898205 |
| End of News | EQS News Service |
|
|
1898205 08.05.2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 1.232,91 | 1.303,90 | 1.360,16 | 1.402,01 | 1.446,09 | 1.463,98 | 1.620,00 | |
| EBITDA1,2 | 125,54 | 125,33 | 80,23 | 101,16 | 105,65 | 105,88 | 117,00 | |
| EBITDA-Margin3 | 10,18 | 9,61 | 5,90 | 7,22 | 7,31 | 7,23 | 7,22 | |
| EBIT1,4 | 64,94 | 56,80 | 10,60 | 30,52 | 36,11 | 40,40 | 53,00 | |
| EBIT-Margin5 | 5,27 | 4,36 | 0,78 | 2,18 | 2,50 | 2,76 | 3,27 | |
| Net Profit (Loss)1 | 51,19 | 44,48 | 2,46 | 30,23 | 26,94 | 40,17 | 34,00 | |
| Net-Margin6 | 4,15 | 3,41 | 0,18 | 2,16 | 1,86 | 2,74 | 2,10 | |
| Cashflow1,7 | 49,50 | 47,30 | 113,30 | 97,50 | 41,30 | 109,00 | 85,00 | |
| Earnings per share8 | 0,73 | 0,65 | 0,02 | 0,42 | 0,38 | 0,58 | 0,51 | |
| Dividend per share8 | 0,29 | 0,00 | 0,00 | 0,00 | 0,15 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: KPMG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Rhön-Klinikum | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 704230 | DE0007042301 | AG | 924,08 Mio € | 19.06.1991 | Halten | 9F2G86FM+GX |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 23,00 | 28,72 | 0,80 | 23,59 | 0,74 | 8,48 | 0,63 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,15 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 03.06.2025 | 08.05.2025 | 07.08.2025 | 07.11.2024 | 27.03.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +7,45% | +12,57% | +38,00% | +32,69% | +452,00% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
